Amgen, Inc. (AMGN) Shares Bought by Rockland Trust Co.

Rockland Trust Co. grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 130.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,786 shares of the medical research company’s stock after acquiring an additional 1,576 shares during the period. Rockland Trust Co.’s holdings in Amgen were worth $484,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Baker Ellis Asset Management LLC bought a new position in shares of Amgen during the third quarter valued at approximately $108,000. Phocas Financial Corp. bought a new position in shares of Amgen during the second quarter valued at approximately $110,000. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares in the last quarter. Omnia Family Wealth LLC boosted its stake in shares of Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Horan Capital Advisors LLC. bought a new position in shares of Amgen during the third quarter valued at approximately $150,000. Institutional investors and hedge funds own 78.95% of the company’s stock.

AMGN has been the topic of a number of recent research reports. Goldman Sachs Group downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, December 12th. Mizuho set a $198.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Sunday, October 29th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective on the stock in a research note on Friday, October 27th. Finally, Cann reiterated a “buy” rating and set a $205.00 price objective on shares of Amgen in a research note on Thursday, November 30th. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Amgen has an average rating of “Hold” and a consensus price target of $191.84.

In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 4,575 shares of company stock valued at $818,361 in the last three months. 0.19% of the stock is currently owned by corporate insiders.

Shares of Amgen, Inc. (AMGN) opened at $183.55 on Friday. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The company has a market cap of $132,295.22, a P/E ratio of 71.42, a P/E/G ratio of 2.26 and a beta of 1.42.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. During the same period in the previous year, the company earned $2.89 EPS. The company’s revenue was down 2.7% on a year-over-year basis. equities analysts forecast that Amgen, Inc. will post 13.21 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a dividend of $1.32 per share. This is a boost from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a yield of 2.88%. Amgen’s dividend payout ratio is presently 205.45%.

Amgen declared that its board has initiated a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/02/17/amgen-inc-amgn-shares-bought-by-rockland-trust-co.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply